CTOR

Over the past six months, Citius Oncology's stock has experienced significant events. The successful U.S. commercial launch of LYMPHIR in December 2025 led to an initial reported revenue of $3.9 million and a stock surge. The company completed strategic financings in December 2025 and May 2026 to support LYMPHIR's commercialization. In April 2026, Nasdaq notified Citius Oncology that its common stock bid price had fallen below the minimum $1.00 per share requirement. The company announced positive topline results from investigator-initiated Phase 1 studies evaluating LYMPHIR in combination with pembrolizumab in relapsed or refractory gynecologic cancers and prior to CAR-T therapy in high-risk diffuse large B-cell lymphoma.